Sodium cromoglicate oral - Emisphere

Drug Profile

Sodium cromoglicate oral - Emisphere

Alternative Names: Cromoglicic acid oral - Emisphere; Cromoglycic acid oral - Emisphere; Cromolyn oral - Emisphere; Cromolyn sodium oral - Emisphere; Oral cromoglicic acid; Oral cromoglycic acid; Oral cromolyn; Oral cromolyn sodium; Oral sodium cromoglicate; Sodium cromoglycate oral - Emisphere

Latest Information Update: 09 May 2011

Price : $50

At a glance

  • Originator Emisphere Technologies
  • Class Antiallergics; Antiasthmatics; Antitussives; Benzopyrans; Chromones; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 08 Aug 2005 Phase-I clinical trials in Allergy in USA (PO)
  • 08 Aug 2005 Phase-I clinical trials in Asthma in USA (PO)
  • 29 Jul 2002 Phase-II clinical trials in Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top